Ginkgo Bioworks Holdings, Inc. (DNA) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Ginkgo Bioworks Holdings, Inc. (DNA) Earnings Overview
As of June 30, 2026, Ginkgo Bioworks Holdings, Inc. (DNA) reported trailing twelve-month net income of -$304M, reflecting +46.5% year-over-year growth. The company earned $-5.11 per diluted share over the past four quarters, with a net profit margin of -183.8%.
Looking at the long-term picture, DNA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$119M in fiscal 2019.
Ginkgo Bioworks Holdings, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including BEAM (-$65M net income, -57.2% margin), TWST (-$81M net income, -20.6% margin), SRPT ($65M net income, -32.5% margin), DNA has room to improve margins relative to the peer group. Compare DNA vs BEAM →
DNA Earnings vs Peers
Earnings metrics vs comparable public companies
DNA Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$313M | +42.8% | -$315M | $-5.64 | -183.8% | -185.3% |
| 2024 | -$547M | +38.7% | -$560M | $-10.54 | -240.9% | -246.5% |
| 2023 | -$893M | +57.6% | -$864M | $-18.40 | -355.1% | -343.8% |
| 2022 | -$2.10B | -15.0% | -$2.21B | $-50.20 | -440.6% | -462.4% |
| 2021 | -$1.83B | -1345.4% | -$1.83B | $-55.53 | -583.1% | -582.6% |
| 2020 | -$127M | -6.1% | -$137M | $-4.00 | -165.2% | -178.8% |
| 2019 | -$119M | - | -$72M | $-4.15 | -220.2% | -132.1% |
Download Data
Export DNA earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DNA — Frequently Asked Questions
Quick answers to the most common questions about buying DNA stock.
What is DNA earnings per share (EPS)?
DNA trailing twelve-month (TTM) diluted EPS is $-5.11, reflecting +46.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Ginkgo Bioworks Holdings, Inc.'s net income?
Ginkgo Bioworks Holdings, Inc. (DNA) trailing twelve-month net income is $-304M as of 2025. Earnings grew +46.5% year-over-year.
Is DNA profitable?
DNA is not currently profitable on a TTM basis, reporting a net loss of $-304M. Net margin is -183.8%. Investors should monitor for a return to profitability.
What is DNA's earnings growth rate?
DNA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are DNA's profit margins?
Ginkgo Bioworks Holdings, Inc. net profit margin is -183.8%, operating margin is -185.3%, and gross margin is +81.5%. Below-average margins reflect competitive or cost pressures. Return on Equity is -51.1%.
Is DNA growing earnings?
Yes, DNA earnings are accelerating — EPS growth of +46.5% exceeds the 5-year CAGR of N/A. TTM net income reached $-304M. Earnings momentum is strengthening.
What was DNA's best earnings year?
Ginkgo Bioworks Holdings, Inc.'s highest annual net income on record is $-119M, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were DNA's earnings last quarter?
DNA's most recent reported quarter was Q1 2026. Net income was $-83M with diluted EPS of $-1.39. For a full breakdown of all quarters, see the quarterly earnings table on this page.